RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors
- 24 October 2005
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 25 (9), 1340-1348
- https://doi.org/10.1038/sj.onc.1209169
Abstract
Tumors comprise genetically heterogeneous cell populations, whose growth and survival depend on multiple signaling pathways. This has spurred the development of multitargeted therapies, including small molecules that can inhibit multiple kinases. A major challenge in designing such molecules is to determine which kinases to inhibit in each cancer to maximize efficacy and therapeutic index. We describe an approach to this problem implementing RNA interference technology. In order to identify Akt-cooperating kinases, we screened a library of kinase-directed small interfering RNAs (siRNAs) for enhanced cancer cell killing in the presence of Akt inhibitor A-443654. siRNAs targeting casein kinase I gamma 3 (CSNK1G3) or the inositol polyphosphate multikinase (IPMK) significantly enhanced A-443654-mediated cell killing, and caused decreases in Akt Ser-473 and ribosomal protein S6 phosphorylation. Small molecules targeting CSNK1G3 and/or IPMK in addition to Akt may thus exhibit increased efficacy and have the potential for improved therapeutic index.Keywords
This publication has 48 references indexed in Scilit:
- Strategies to overcome resistance to targeted protein kinase inhibitorsNature Reviews Drug Discovery, 2004
- SRCircumventing imatinib resistanceCancer Cell, 2004
- A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2Published by Elsevier BV ,2004
- Structure, regulation and function of PKB/AKT—a major therapeutic targetBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2004
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJCI Insight, 2003
- Issues and progress with protein kinase inhibitors for cancer treatmentNature Reviews Drug Discovery, 2003
- BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood, 2003
- The Human Homolog of the Rat Inositol Phosphate Multikinase Is an Inositol 1,3,4,6-Tetrakisphosphate 5-KinasePublished by Elsevier BV ,2002
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Oncogenic kinase signallingNature, 2001